Buy Call on iRhythm Technologies (IRTC) Based on Innovative Cardiac Monitoring
+6.40%current return
"iRhythm is a 5 billion market cap company that does cardiac monitoring. The combination of product innovation, clinical outcomes and FDA compliance has positioned them for growth in the high teens, low 20s over the next couple of years. We are pretty excited about this company and it could be a buyout candidate."
— Greg Torto
iRhythm Technologies (IRTC) is presented as an attractive small cap play due to its innovative cardiac monitoring products, strong clinical endorsements, and potential for a buyout. The team expects growth in the high teens to low 20 percent range over the next couple of years, making it a clear buy signal for investors looking for exposure in medical technology.
High ConvictionScore: 8.3
Stock Idea •Barron's Live • 2 months ago